# Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

> **NCT07628062** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- HPV-Positive Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **DRUG:** Nogapendekin Alfa Inbakicept (NAI)
- **BIOLOGICAL:** hAd5-HPV Vaccine (IBRX-042)
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** De-Intensified IMRT
- **RADIATION:** Standard of Care IMRT

## Key facts

- **NCT ID:** NCT07628062
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2030-12-31
- **Final completion:** 2031-06-27
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628062, "Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07628062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*